Swedbank
PTGX icon

Swedbank’s Protagonist Therapeutics PTGX Stock Holding History

Swedbank’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$1.93M – 709
2024
Q4 		$1.93M Hold
50,000
– – ﹤0.01% 623
2024
Q3 		$2.25M Buy
+50,000
New +$2.02M ﹤0.01% 604

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Swedbank's PTGX Position: Q1 2025 in Review

Swedbank sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 50,000 shares — an estimated $1.93M sold.

Swedbank first reported a position in PTGX in Q3 2024 and held it in 2 quarters. The position peaked at $2.25M in Q3 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Swedbank reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Swedbank sold 50,000 Protagonist Therapeutics shares in Q1 2025, an estimated $1.93M.
  • Swedbank first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 2 quarters.
  • Swedbank's Protagonist Therapeutics position peaked at $2.25M in Q3 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Swedbank's 13F filing for Q1 2025, filed 14 Apr 2025.